Grid Therapeutics is a biotech company based on the innovative science first developed by Edward F. Patz, Jr. MD and his team of scientists at Duke University Medical Center. Located in Durham, North Carolina, Grid is developing the first human derived targeted immunotherapy for cancer. The antibody was discovered in exceptional outcome early stage lung cancer patients who did not progress to develop metastasis. The antibody was isolated from patient’s B-cells using state of the art molecular genomic techniques. “GT103”, the company’s lead asset, is currently enrolling the first-in-man Phase 1 clinical trial in refractory NSCLC patients.
Company Details
- Employees
- 4
- Founded
- -
- Address
- Durham, North Carolina, Us
- Phone
- 919-987-7190
- in****@****thr.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- gridtherapeutics.com
- HQ
- Durham, North Carolina
Grid Therapeutics Questions
Grid Therapeutics's helpline number is 919-987-7190
Grid Therapeutics's website is gridtherapeutics.com
Grid Therapeutics's LinkedIn profile is https://www.linkedin.com/company/grid-therapeutics
Grid Therapeutics has
4 employees.
View email and phone details for 4
employees at Grid Therapeutics.
Grid Therapeutics's industry is
Biotechnology Research
Grid Therapeutics's top competitors are
Tavros Therapeutics,
Madera Therapeutics,
Tregtherapeutics Inc.,
Incyclix Bio,
Glycan Therapeutics,
Evecxia Therapeutics, Inc.,
Belhaven Biopharma,
Immvention Therapeutix, Inc.,
Infinimmune,
Tenax Therapeutics.
Grid Therapeutics's support email address is info@gridthr.com
Grid Therapeutics's categories are Biotechnology Research
Grid Therapeutics's founding year is 2014
